BERKELEY HEIGHTS, N.J., July 18, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that effective July 11, 2011, Cyclacel Limited, a wholly-owned subsidiary of the Company, entered into an amendment of its license agreement, dated September 10, 2003 between Cyclacel Limited and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) relating to certain rights which Cyclacel Limited has licensed from Daiichi Sankyo with regard to the Company’s sapacitabine drug.
